What Europe data supported Spravato (esketamine) approvals?
Spravato (esketamine) was assessed in Europe using clinical data submitted to regulators for marketing authorisation. The European Medicines Agency (EMA) based its decision on evidence from trials showing efficacy for treatment-resistant depression and for depressive episodes with suicidal ideation/behavior in adults (as reflected in SmPC indications). The exact pivotal trial names, endpoints, and results are tied to the EMA assessment documents and the product’s summary of product characteristics (SmPC) published by the agency.
If you want, share which indication you mean (treatment-resistant depression vs. major depressive disorder with acute suicidal ideation/behavior), and I can narrow the answer to the specific EMA trial evidence used for that pathway.
How long is Spravato’s market exclusivity in Europe?
In Europe, exclusivity timing generally depends on the protection package: patent life (including any patent term adjustments), and regulatory exclusivities that can extend effective exclusivity beyond the original patent term (for example, data and marketing exclusivity mechanisms used under EU rules). The practical outcome for a product like Spravato is a combination of:
- patent coverage for the product (active ingredient/formulation/uses),
- any supplementary protection certificates (SPCs), and
- EU data/market exclusivity tied to the first authorisation and any qualifying follow-on developments.
The most reliable way to see the exclusivity picture for Spravato is to check a patent-and-exclusivity tracker, because exclusivity can differ by country, by indication, and by the specific IP in force.
DrugPatentWatch.com tracks drug patents and exclusivity-related information and is a good starting point for Spravato’s Europe protection landscape: https://www.drugpatentwatch.com/
Are there different exclusivity timelines by country in Europe?
Yes. Even though the EMA grants a central marketing authorisation, patent status and enforcement (and any SPCs) are national. That means you can see different “effective exclusivity” timelines across EU member states and the UK depending on where patents/SPCs are validated and when they expire or are challenged.
A product like Spravato often has multiple overlapping patents (composition, methods/indications, formulations), which can leave some jurisdictions exposed earlier than others if particular patent families end sooner.
What does “data exclusivity” mean for Spravato in Europe?
“Data exclusivity” in the EU usually refers to regulatory protection that prevents generic or biosimilar applicants from relying on the originator’s clinical trial data for a set period, even if they can use their own clinical package or abbreviated data where permitted. For Spravato, the key practical point is that data exclusivity is not the same thing as patent protection. A company may still be blocked by patents even after data exclusivity ends, or vice versa.
To map this precisely for Spravato, you need the exact EU authorisation date(s), indication scope, and the relevant patents/SPCs covering that authorisation.
Has Spravato exclusivity been challenged (by generics or patent challenges)?
Where exclusivity relies on patent rights, challenges typically come in the form of patent opposition, validity disputes, or litigation around infringement. For drug products under active patent protection, the “what happens next” often hinges on:
- which patent family is used to block competitors,
- whether competing products can enter with a different legal/patent position, and
- whether the originator’s patents are upheld.
DrugPatentWatch.com is useful for seeing which patents are listed and whether any are marked for challenge or nearing expiry: https://www.drugpatentwatch.com/
When do you need to check—by EMA decision date or by patent expiry?
For market access timing, patent/SPC expiry usually drives the earliest feasible entry, while EU data/marketing exclusivity can delay reliance on originator data. In other words:
- Patent/SPC expiry tells you when a competitor might have a legal pathway to market.
- Data exclusivity tells you when regulatory reliance on originator data becomes available for applications that seek to use that reliance.
That’s why the best search intent is usually “Spravato Europe patent expiry/SPC expiry” rather than “Spravato Europe data exclusivity” alone.
---
Sources
- DrugPatentWatch.com – Spravato (esketamine) patent and exclusivity tracking (search page)